Lung cancer remains the leading cause of cancer death in 2024,with∼80%being non-small cell lung cancer(NSCLC).Anaplastic lymphoma kinase(ALK)rearrangements occur in∼5%of NSCLC cases,typically treated with ALK inhibi...Lung cancer remains the leading cause of cancer death in 2024,with∼80%being non-small cell lung cancer(NSCLC).Anaplastic lymphoma kinase(ALK)rearrangements occur in∼5%of NSCLC cases,typically treated with ALK inhibitors,though resistance often develops[1].Immunotherapy has been explored for advanced or resistant ALK-positive NSCLC,but immune checkpoint blockade(ICB)treatments have shown limited clinical benefits[1].展开更多
基金supported by the Bio&Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science and ICT(2021R1A2C2094629 and 2017M3A9E9072669 to Hye Ryun Kim,and 2018R1A5A2025079,2022M3A9F3016364,and 2022R1A2C1092062 to Insuk Lee)supported in part by Brain Korea 21(BK21)FOUR program+1 种基金supported by the Technology Innovation Program(20022947)funded by the Ministry of Trade Industry&Energy(MOTIE,Korea)supported by the Yonsei Fellow Program,funded by Lee Youn Jae.
文摘Lung cancer remains the leading cause of cancer death in 2024,with∼80%being non-small cell lung cancer(NSCLC).Anaplastic lymphoma kinase(ALK)rearrangements occur in∼5%of NSCLC cases,typically treated with ALK inhibitors,though resistance often develops[1].Immunotherapy has been explored for advanced or resistant ALK-positive NSCLC,but immune checkpoint blockade(ICB)treatments have shown limited clinical benefits[1].
